Lexeo Therapeutics, Inc. is a clinical stage genetic medicine company that focuses on hereditary and acquired diseases. The company is headquartered in New York, New York.
| Revenue (TTM) | 0 |
| Gross Profit (TTM) | $-62.33M |
| EBITDA | $-97.18M |
| Operating Margin | 0.00% |
| Return on Equity | -54.80% |
| Return on Assets | -32.50% |
| Revenue/Share (TTM) | $0.00 |
| Book Value | $3.13 |
| Price-to-Book | 1.59 |
| Price-to-Sales (TTM) | 478.26 |
| EV/Revenue | 416.34 |
| EV/EBITDA | -6.02 |
| Quarterly Earnings Growth (YoY) | 0.00% |
| Quarterly Revenue Growth (YoY) | 0.00% |
| Shares Outstanding | $78.52M |
| Float | $47.28M |
| % Insiders | 0.60% |
| % Institutions | 114.63% |
Volatility is currently expanding
Lexeo Therapeutics, Inc. (LXEO) Discusses Phase III Program Design and Durable Cardiac Improvements in Friedreich's Ataxia Transcript
Lexeo Therapeutics is a clinical-stage gene therapy company focused on inherited cardiac diseases. Their main value driver is LX2006 for Friedreich's ataxia (FA) cardiomyopathy. LX2006 currently has a clearer SUNRISE-FA 2 pivotal path, and we should get its topline data by 2H2027.
Published findings in JAMA Cardiology demonstrate LX2006 generally well tolerated, with early signs of efficacy in Phase I/II studies
Lexeo Therapeutics, Inc. (LXEO) Shareholder/Analyst Call Transcript
SUNRISE-FA 2 study parameters include LVMI primary endpoint, 6-month topline efficacy analysis, inclusion criteria focused on abnormal baseline LVMI and open-label trial design
NEW YORK, May 19, 2026 (GLOBE NEWSWIRE) -- Lexeo Therapeutics, Inc. (Nasdaq: LXEO), a clinical stage genetic medicine company dedicated to pioneering novel treatments for cardiovascular diseases, today announced that the Company will participate in a fireside chat at the 2026 RBC Capital Markets Global Healthcare Conference on Tuesday, May 19, 2026 at 2:35 p.m. ET in New York, NY.
SUNRISE-FA 2 open-label, pivotal trial protocol and SAP for LX2006 submitted to FDA in Q1 2026; Awaiting final FDA feedback Multiple presentations highlighting progress across cardiac genetic medicine pipeline and optimized, Sf9-baculovirus AAV manufacturing platform to be presented at ASGCT 2026 Appointed Laura Sepp-Lorenzino, Ph.D. to Board of Directors Cash, cash equivalents and investments of $227.6 million expected to provide operational runway into 2028 NEW YORK, May 11, 2026 (GLOBE NEWSWIRE) -- Lexeo Therapeutics, Inc. (Nasdaq: LXEO), a clinical stage genetic medicine company dedicated to pioneering novel treatments for cardiovascular diseases, today provided business updates across its portfolio and reported financial results for the first quarter 2026.
